Increased Life Science Sales, Acquisitions Help PerkinElmer Q4 Revenue Grow 10 Percent
PerkinElmer this week said fourth-quarter 2006 revenues increased 10 percent as R&D spending rose 29 percent and profit fell 70 percent.
The company also this week declared a quarterly dividend of $.07 per share of common stock, to be payable on May 11.
Total receipts for the three months ended Dec. 31, 2006, increased to $427 million from $388 million year over year, PerkinElmer said.
Revenue for the company’s Life and Analytical Sciences business was up 12 percent to $321 million year over year. Meantime, Optoelectronics revenue was up 5 percent to $106 million and “other” revenue was down 11 percent to $8.5 million year over year.
Health Sciences receipts represented 85 percent of revenue for the quarter and was “driven by genetic screening, medical imaging, environmental and service businesses,” and from acquisitions and new product launches.
CEO Gregory Summe said the results reflect growth coming through “R&D and capital investments in our key growth platforms,” and from the eight companies it acquired over the previous year.”
R&D spending in the quarter increased to $27 million from $21 million year over year.
PerkinElmer said fourth-quarter profit tumbled to $41.8 million from $187.5 million in the year-ago period.
PerkinElmer most recently acquired Euroscreen, Evotec Technologies, Triton’s thermal analysis product line, and Avalon Instruments.
“We expect to carry this momentum into 2007, bringing an increased number of new products to market while continuing to deliver strong financial results,” Summe said.
PerkinElmer said it expects full-year 2007 revenue to climb “in the high single to low double digits.”
PerkinElmer had around $191 million in cash and cash equivalents and $7.5 million in marketable securities and investments as of Dec. 31, 2006.
BD Fiscal Q1 Revenues Rise 10 Percent, R&D Surges 185 Percent, Profit Slides 35 Percent
Becton Dickinson this week said fiscal first-quarter 2007 revenues increased 8 percent as R&D spending surged 185 percent and profit dropped 35 percent.
Total receipts for the three months ended Dec. 31, 2006, increased to $1.5 billion from $1.4 billion year over year.
BD said revenues from its Diagnostics segment increased 2 percent to $442 million, while Biosciences revenue increased 11 percent to $232 million. Revenue from the Medical segment climbed 10 percent to $826 million.
R&D spending for the quarter increased to $195 million from $68.3 million year over year. Contributing to the increase was a $115-million charge related to the completion of its acquisition of TriPath Imaging.
Net profits for the quarter slid to $142.9 million from $217.9 million in the year-ago period.
The company did not disclose its cash holdings.
Vanderbilt, University of Michigan Join Sigma's RNAi Partnership Program
Research centers at Vanderbilt University and the University of Michigan have joined Sigma-Aldrich’s RNAi Partnership Program, part of the RNAi Consortium, the company said this week.
Terms of the membership call for the Vanderbilt-Ingram Cancer and the Comprehensive Cancer Center at the University of Michigan to receive Sigma-Aldrich genomics products, including the TRC shRNA libraries for human and mouse genes, the company said.
Shawn Levy, scientific director of microarray shares resource at the VICC, said the group’s researchers are working on targeted gene-knockdown projects, and said access to the shRNA library will “greatly accelerate their ability to prioritize genes identified from various proteomic and genomic screens."
University of Michigan professor Mikhail Nikiforov said having access to the library is “extremely important for assessing specificity and efficacy of new and existing pharmaceutical agents designed for inhibition of genes and proteins.”
Sigma-Aldrich said it uses its the RNAi Partnership Program to advance functional genomics research by giving academic researchers access to the company’s new technologies and select IP. Other partnering organizations include Washington University, Princeton University, Rutgers University.
BioImagene to Bundle Image Data-Analysis Software with HP Servers
BioImagene this week announced a collaboration with HP to bundle its high-content analysis and digital pathology platforms with HP servers.
BioImagene said that the integration of the technologies will allow for better management of the huge amounts of images and data generated in discovery, life sciences, and clinical laboratories.
BioImagene products include CellMine, TissueMine, and 3i. Bundling of BioImagene technologies with HP servers will offer users a cost-effective solution for rapid image analysis, image processing, and image management on a proven platform for life sciences, drug discovery, and digital pathology work, the company said.
“By implementing BioImagene’s Image Management system on HP platforms, we have enabled scientists to access images and research data quickly and easily,” Randy Chen, project leader of research informatics at Allergan, said in a statement. “The solution from BioImagene and HP is expected to provide powerful hardware and image management expertise to the image informatics community and accelerate discovery research even more cost efficiently.”
Financial details were not disclosed.
Aruna Biomedical Licenses hESC Tech from U of Georgia
Aruna Biomedical said this week that it has entered into a technology licensing agreement with the University of Georgia Research Foundation that will enable the company to commercialize human neural progenitor cell technology developed at the university.
Under the terms of the agreement, Aruna has acquired an exclusive worldwide license to develop and commercialize neural cells derived from human embryonic stem cells. Aruna will offer the academic and industry research communities access to these cells, which will relate to normal and diseased human conditions.
Aruna said that the cells can be used in research on Alzheimer's, spinal cord injury, and depression. The company anticipates launch of its first product, human neural progenitor cells, in early 2007, with additional products to follow. The human NP cells will be sold and marketed through an undisclosed third-party distribution partner and packaged as a kit with growth media and substrates.
Founded in 2003, Aruna Biomedical is a privately held biotechnology firm focused on emerging technologies in human embryonic stem cell research for use in drug discovery and neuroscience research.
Cellexus Biosystems Sells First Cell Bioreactors
Cellexus Biosystems this week said that it has generated its first revenues from multiple sales of its CellMaker Lite cellular bioreactor system.
The company said that it is unable to disclose its customers’ identities due to confidentiality agreements. However, it said that it has shipped seven systems in the US, UK, and Australia.
Cellexus, located in Cambridgeshire, UK, said its customers include major pharmaceutical companies, a “world-class” academic institution, a distributor, and a supplier to the industry.